We are live on !
Find out more
Ulys LLC Portfolio holdings
AUM
$25.4M
Turnover
0%
1-Year Est. Return
201.03%
This Fund
S&P 500
This Quarter Est. Return
-35.46%
1 Year Est. Return
+201.03%
3 Year Est. Return
-31.51%
5 Year Est. Return
-50.88%
10 Year Est. Return
–
AUM
$27.5M
AUM Growth
-$14.5M
(-34%)
Cap. Flow
+$537K
Cap. Flow % of AUM
Cap. Flow %
1.95%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
2
New
–
Increased
1
Reduced
–
Closed
–
Avg Time Held
1.5
years
Top 10 Avg Time Held
1.5
years
Top 20 Avg Time Held
1.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lexicon Pharmaceuticals
LXRX
|
+$537K |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.97% |
| 2 | Miscellaneous | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Lexicon Pharmaceuticals
LXRX
$784M
| $27.5M | 99.97% |
4,321,215
+66,557
| +2% | +$537K |
2013 Q2
6 quarters
|
|
2
DELISTED
CERES, INC. COMMON STOCK NEW
CERE
| $7K | 0.03% |
3,891
| – | – |
2013 Q2
6 quarters
|
|
Similar funds
AGEC
Ulys LLC's Q4 2014 Portfolio in Review
As of Q4 2014, Ulys LLC held 2 positions worth $27.5M, down 34% from $42M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Trading was light in Q4 2014: portfolio turnover was 0%. Ulys LLC opened no new positions and made no exits, leaving the 2-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
- Ulys LLC added most to Lexicon Pharmaceuticals in Q4 2014, an estimated $537K increase.
- Ulys LLC's ten largest holdings make up 100% of its $27.5M portfolio in Q4 2014.
- Ulys LLC opened 0 new positions and closed 0 in Q4 2014.
- Ulys LLC's portfolio value fell 34% quarter-over-quarter to $27.5M.
Based on Ulys LLC's 13F filing for Q4 2014, filed 12 Feb 2015.